Copy Link Print Information

ST 2825

71 Cited Publications
Revisión del cliente

Based on 71 publication(s) in Google Scholar

ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.92%
  • No. CAS: 894787-30-5
  • Fòrmula: C27H28Cl2N4O5S
  • Peso molecular:591.51
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • ST 2825 Chemical Structure
    ST 2825 Chemical Structure
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
  • Experimental Validation Results for ST 2825
No. CAS: 894787-30-5
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) ST 2825

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • ST 2825 Chemical Structure
    ST 2825 Chemical Structure
    1/16
  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2019 May;234(5):7645-7658. [Abstract]

    Customer Validation
     Western blot analysis shows the level of NFATc1 in cells stimulated with RANKL in the presence or absence of ST 2825.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Nov:64:33-41. [Abstract]

    Customer Validation
     Western blot analysis of the protein levels of the phosphorylated NF-κB P65 levels, and the phosphorylated ERK levels in U251 cells, pre-treated with the indicated concentrations of ST2825 (ST) for 24 h, and re-treated with 1 μg/mL LPS for 1 h.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936. [Abstract]

    Customer Validation
     Western blot analysis of p65 and cleaved caspase 3 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits nuclear p65 in osteosarcoma cells, and significantly increases cleaved caspase 3 protein expression.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936. [Abstract]

    Customer Validation
     Western blot analysis of cyclin D1 and MMP 9 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits cyclin D1 expression in osteosarcoma cells, and significantly increases MMP9 protein expression.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2017 Sep:295:23-35. [Abstract]

    Customer Validation
     Western blotting analysis of the Tyr1472-phosphorylation of the NR2B subunit in the hippocampus of experimental rats under the various treatment conditions. ST2825 (10 μg in 2 μL) is injected. Representative Western blotting bands corresponding to the specific proteins and the various pharmacological treatments.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Nov 17;7(1):15797. [Abstract]

    Customer Validation
     Representative Western blot to show the level of MyD88 protein. The upper panel shows representative protein levels of MyD88. Tubulin is detected as a loading control. The bottom panel shows quantitative data of MyD88.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2017 Nov;37(11):6203-6209. [Abstract]

    Customer Validation
     Effect of ST2825 on the expression of myeloid differentiation primary response gene 88 (MYD88) and nuclear factor kappa B (NF-ĸB) signaling proteins. Cells are cultured with 100 μM ST2825 for 6 h and analysed for protein expression by immunoblotting. DMSO is used as a vehicle control and α-tubulin as a loading control.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Brain Res. 2016 Jul 15:1643:130-9. [Abstract]

    Customer Validation
     Effect of ST2825 treatment on the expression of MyD88 at 24h after TBI. Levels of MyD88 are significantly increased at 24 h after TBI. ST2825 (20 μg/μL) treatment reduces the levels of MyD88 at 24 h post TBI. No difference is detected between the TBI group and TBI+vehicle group.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Genet Mol Res. 2016 Mar 4;15(1):15016826. [Abstract]

    Customer Validation
     Effect of ST2825 on IκB, cyclin D1, cleaved caspase-3, and bcl-2 expression in HepG-2 cells as determined by western blot analysis (lane 1, blank; lane 2, control; and lane 3, high-dose ST2825). Compared with the control, 24 h of ST2825 treatment significantly inhibits cyclin D1 and bcl-2 expression (P>0.05), but 24-h treatment with ST2825 significantly increases cleaved caspase-3 expression (P<0.05) in the high-dose group.

  • 1/16

    ST 2825 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2015 Jul;12(1):895-904. [Abstract]

    Customer Validation
     The degradation of IκBα and nuclear translocation of p65 induced by IL-1β are also dramatically blocked by pretreatment of the cells with TLR2Ab, ST2825 and TPCA-1. The cultured leukocytes are obtained from a normal control mouse and stimulated with IL-1β (10 ng/ml) for 1 h with or without pre-treatment of BML-111 (1 mM) for 30 min, BOC1 (100 μM) for 30 min, TLR2Ab (1 μg/mL) for 1 h, goat IgG (1 μg/mL) for 1 h, ST2825 (20 μM) for 1 h or TPCA-1 (10 μM) for 1 h. The western blot is representative

  • ST 2825